13 results
6-K
EX-99.1
MOR
Morphosys AG
23 Mar 22
Current report (foreign)
4:15pm
are expected to more than offset potential negative factors such as drug pricing, a recently active U.S. Federal Trade Commission agenda and tax rate increases
6-K
EX-99.1
MOR
Morphosys AG
16 Mar 22
2021 Annual Report A nn ua l R ep or t 20 21
4:55pm
offset potential negative factors such as drug pricing, a recently active U.S. Federal Trade Commission agenda and tax rate increases. Future Research
6-K
EX-99.1
MOR
Morphosys AG
23 Mar 21
Current report (foreign)
3:53pm
the regulatory and tax environment and drug pricing policies. Deal activity is expected across all subsectors and transaction sizes, with large pharma companies
6-K
EX-99.1
u3s3js
22 Mar 21
Current report (foreign)
12:42pm
6-K
EX-99.1
zb0tf4 xy9g07
27 Mar 20
Current report (foreign)
3:29pm
6-K
EX-99.1
yfplhq8opc8s47tj9pi
20 Mar 20
Current report (foreign)
2:15pm
6-K
EX-99.1
bfqsj
21 Mar 19
Current report (foreign)
6:14am
6-K
EX-99.1
ovtvx5 26p
15 Mar 19
2018 annual report Morphosys Engineering the Medicines of Tomorrow
6:27am
20-F
66csas9ewx k20fawiwp
13 Mar 19
Annual report (foreign)
5:13pm
- Prev
- 1
- Next